Next Article in Journal
A Novel Cold-Adapted Leucine Dehydrogenase from Antarctic Sea-Ice Bacterium Pseudoalteromonas sp. ANT178
Next Article in Special Issue
Discovery of an Unusual Fatty Acid Amide from the ndgRyo Gene Mutant of Marine-Derived Streptomyces youssoufiensis
Previous Article in Journal
Metabolomic Investigations on Nesterenkonia flava Revealed Significant Differences between Marine and Terrestrial Actinomycetes
Previous Article in Special Issue
Characterization of the Microbial Population Inhabiting a Solar Saltern Pond of the Odiel Marshlands (SW Spain)
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Chrysoxanthones A–C, Three New Xanthone–Chromanone Heterdimers from Sponge-Associated Penicillium chrysogenum HLS111 Treated with Histone Deacetylase Inhibitor

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Key Laboratory of Biosynthesis of Natural Products of National Health Committee, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nong Tan Street, Beijing 100050, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Mar. Drugs 2018, 16(10), 357; https://doi.org/10.3390/md16100357
Submission received: 11 September 2018 / Revised: 26 September 2018 / Accepted: 28 September 2018 / Published: 1 October 2018
(This article belongs to the Special Issue Genome Mining and Marine Microbial Natural Products)

Abstract

:
By treating with histone-deacetylase inhibitor valproate sodium, three new heterdimeric tetrahydroxanthone–chromanone lactones chrysoxanthones A–C (13), along with 17 known compounds were isolated from a sponge-associated Penicillium chrysogenum HLS111. The planar structures of chrysoxanthones A–C were elucidated by means of spectroscopic analyses, including MS, 1D, and 2D NMR. Their absolute configurations were established by electronic circular dichroism (ECD) calculations. Chrysoxanthones A–C exhibited moderate antibacterial activities against Bacillus subtilis with minimum inhibitory concentration (MIC) values of 5–10 μg/mL.

1. Introduction

The Penicillium chrysogenum species is commonly used in the industrial production of β-lactam antibiotics. This species is present in various habitats including plants, gorgonians, marine sediments, algae, sponges, and mangroves. The whole genome of the strain P. chrysogenum Wisconsin 54-1255 was sequenced in 2008, and up to 33 secondary metabolic gene clusters were predicted, showing huge potential to produce various types of compounds in addition to β-lactam antibiotics [1]. However, limited products with six chemical types were obtained from P. chrysogenum, much fewer than the estimated number that the secondary metabolic gene clusters could generate. Therefore, it is believed that many of the secondary metabolic gene clusters may be silent in laboratory culture conditions. In recent years, strategies related to epigenetic modifications, such as the addition of a histone-deacetylase inhibitor and disruption of gene-encoding histone deacetylase (HDAC) have been proven to be able to effectively activate the silent biosynthetic gene clusters and lead to the formation of diverse secondary metabolites in fungi [2,3,4,5].
The effects of HDAC inhibitors (valproic acid (VPA), suberoylanilide hydroxamic acid (SAHA), sodium butyrate (NaBu)) on the production of secondary metabolites of a sponge-associated fungus, P. chrysogenum HLS111, have been examined. As a result, the strain cultured with VPA produced more compounds than those of the control, and the contents of some compounds were much higher than those of the control (Figure 1). In this study, the differential parts of a crude extract of the test group attracted our attention, and its subsequent separation and purification provided three new tetrahydroxanthone—chromanone lactone heterdimers, designated chrysoxanthones A–C (13, Figure 2), and 17 known compounds (420, Supplementary Materials Figure S1). Herein, we report the isolation, structure elucidation, and biological activities of these compounds. Finally, the biosynthetic pathway of chrysoxanthones A–C was proposed.

2. Results and Discussion

2.1. Structure Elucidation of Compounds

The organic extract of P. chrysogenum HLS111 treated by VPA was purified by repeated silica-gel chromatography, reversed-phase chromatography, as well as semipreparative HPLC to yield compounds 120. Chrysoxanthones A–C (13) were new isomerides that shared the common molecular formula of C32H30O14, determined by HRESIMS {m/z 639.1716 [M + H]+ (compound 1), m/z 639.1712 [M + H]+ (compound 2), m/z 639.1713 [M + H]+ (compound 3), calcd for C32H31O14 639.1714}, requiring 18 degrees of unsaturation. Compounds 13 have similar ultraviolet spectral properties λmax (log ε) 248.2 (3.6), 335.5 (3.6) nm, indicating that they share related skeletons.
Chrysoxanthones A (1) and B (2) were attained as a pale yellow powder. They showed identical 1H and 13C NMR spectra (Table 1, Supplementary Materials Figures S4, S5, S10, and S11), despite they were separated using a nonenantioselective method, presuming they were isomers but not enantiomers. By comparison of the NMR data (Table 1) with the structurally related compounds, they were identified as the tetrahydroxanthone–chromanone lactone heterdimers [6,7,8]. The HMBC correlations of H-3 to C-6′ and H-7 to C-2 indicated the monomers of compounds 1 and 2 were connected by a 2-6′ linkage (Figure 3, Supplementary Materials, Figures S6 and S12). The 1H and 13C NMR data (Table 1) of 1 and 2 were in agreement with those for blennolide J [6], which suggested they might have the same planar structures. The key coupling constants in 1H NMR spectra (Table 1, Supplementary Materials, Figures S4 and S10), the key Rotating Frame Overhauser Effect Spectroscopy (ROESY) correlations (Figure 4) and NMR data rules could prove the relative stereochemistry of 1 and 2. The trans-configuration of H-5 and H-6 of the tetrahydroxanthone monomer was established by chemical shifts (compounds 1 and 2 δ5-H/C 3.93/76.9, δ6-H/C 2.42/29.2 vs. blennolide I δ5-H/C 4.12/71.3, δ6-H/C 2.11/28.5; cis-configuration) and the coupling constant (3JH-5/H-6 = 11.5 Hz) [6], as well as the ROESY correlation between H-5 (δH 3.93) and H-11 (δH 1.18). The ROESY correlation between H-13 (δH 3.68) and H-6 (δH 2.38) revealed the relative configurations of chiral carbons 5, 6, and 10a to be (5S, 6R, 10aS, or 5R, 6S, 10aR) (Figure 4C). Coupling constant 3JH-9′/H-10′ = 4.0 Hz established the trans-configuration of H-9′ and H-10′ of the β-methyl-γ-lactone moiety. Since the biaryl bond could rotate, it was ambiguous to determine the relative stereochemistry of carbon 2′ based on ROESY correlations. However, a summary of the NMR data [6,7,8] could provide some clues to identify the relative configurations of C-2′ and C-10′. When the difference between the H-3a’ and H-3b’ values was greater than 0.41 ppm, the relative configurations were proposed to be 2′S, 10′R or 2′R, 10′S, while when it was less than 0.19 ppm, the relative configuration was 2′S, 10′S or 2′R, 10′R. Thus, the relative configurations of 1 and 2 were the same as those of blennolide J [6], but the optical rotation data and CD spectra of compounds 1 and 2 were opposite to those of blennolide J (compound 1 [ α [ D 20 +30.8 (c 0.05, MeOH), compound 2 [ α [ D 20 +58.4 (c 0.15, MeOH), blennolide J [ α [ D 20 −93.5 (c 0.08, CHCl3)) [6], indicating the absolute configurations of two subunits of compounds 1 and 2 were the same or enantiotropic to those of blennolide J. Then, the absolute structures of compounds 1 and 2 were suggested to be (1a/2a (5R,6S,10aR,2′S,9′S,10′S); 1b/2b (5R,6S,10aR,2′R,9′R,10′R); 1d/2d (5S,6R,10aS,2′R,9′R,10′R)). The absolute configurations of compounds 1 and 2 were determined by comparing experimentally measured CD spectra with those calculated with the Time-Dependent Density Functional Theory (TD-DFT) method. The experimental electronic circular dichroism (ECD) spectrum of compounds 1 and 2 matched very well with the theoretical ECD spectrum for 1a(5R,6S,10aR,2′S,9′S,10′S) and 2b(5R,6S,10aR,2′R,9′R,10′R) (Figure 5A,B), respectively, confirming the absolute structures of 1 and 2.
Compound 3 was also isolated as a pale yellow powder. Its NMR spectroscopic data were similar with that of compounds 1 and 2, except the chemical shifts [H-3a’ (δH 3.05), H-3b’ (δH 3.21), H-9′ (δH 4.45); C-3′(δC 39.6), C-9′(δC 87.5)] moved to [H-3a’ (δH 3.10), H-3b’ (δH 3.51), H-9′ (δH 4.38); C-3′(δC 40.4), C-9′(δC 86.4)] (Table 1). The key HMBC correlations of compound 3 suggested the planar structure of 3 was identical with structures 1 and 2 (Figure 3). The obvious NMR differences might be induced by the change of the stereogenic centers of 2′, 9′, and 10′ in β-methyl-γ-lactone moiety. The trans-configuration of H-9′ and H-10′ (9′S,10′S or 9′R,10′R) of the β-methyl-γ-lactone moiety was uniform with compounds 1 and 2 by the chemical shifts (Table 1) and coupling constant (3JH-9′/H-10′= 3.5 Hz), together with the NOE correlations between H-13′ (δH 1.19) and H-9′ (δH 4.38) (Figure 4B). Therefore, epimerization at C-2′ led to the above NMR differences. The absolute configurations of chiral carbons 2′, 9′, and 10′ were assigned as (2′R,9′S,10′S or 2′S,9′R,10′R), which were in agreement with paecilin B [6]. Above all, the accordance of the experimentally measured CD spectra with the calculated ECD of 3a confirmed the absolute configuration of compound 3 was 5R,6S,10aR,2′R,9′S,10′S (Figure 5C).
The known compounds were identified as andrastins A (keto form, 4 and enol form, 5) [9,10], secalonic acid A (6) [11,12,13,14], secalonic acid D (7) [14], secalonic acid F (8) [14,15], griseoxanthone C (9) [16], norlichexanthone (10) [16], 7-hydroxy-3-(2-hydroxypropyl)-5-methyl-isochromen-1-one (11) [17], 7-hydroxy-3,5-dimethyl-isochromen-1-one (12) [17], penicisimpin B (13) [18], meleagrin (14) [19], oxaline (15) [20], rcqueforcine C (16) [21], citreoindole (17) [22], haenamindole (18) [22], conidiogenone C (19) [23], and conidiogenone D (20) [23] by comparing their spectroscopic data with those reported in the literature (chemical structures in Supplementary Materials Figure S1). Moreover, the NMR data of andrastins A in keto form were reported the first time (Supplementary Materials Table S3).

2.2. Biological Assays

Chrysoxanthones A–C were assayed for antibacterial activities against Staphylococcus epidermidis (ATCC 12228, MSSE), Staphylocccus aureus (ATCC 29213, MSSA), Bacillus subtilis (ATCC 63501), Enterococcus faecalis (ATCC 29212, VSE), and Escherichia coli (ATCC 25922). Chrysoxanthones A–C exhibited the highest antibacterial activities against B. subtilis with minimum inhibitory concentration (MIC) values of 5–10 μg/mL and moderate activities against S. epidermidis and S. aureus with MICs of 10–80 μg/mL (Table 2). Meanwhile, the antitumor activities in vitro of chrysoxanthones A–C were evaluated against human multiform glioblastoma (U87 MG), human nonsmall cell lung cancer (NCI-H1650), human colonic carcinoma (HT29), human renal carcinoma (A498), and human leukemia (HL60) cell lines using the MTT method. Compared with secalonic acid D, the antitumor activities of chrysoxanthones A–C decreased significantly (Supplementary Materials Table S5), indicating that the β-methyl-γ-lactone ring reduced cytotoxicity, supporting that the tricyclic core was essential for bioactivities [6].

2.3. Plausible Biosynthetic Gene Cluster and Pathway of Chrysoxanthones A–C

Based on the common tetrahydroxanthones moiety, we proposed that chrysoxanthones A–C shared the same biosynthetic gene cluster and pathway with those of secalonic acids. The biosynthetic gene cluster of secalonic acids in Claviceps purpurea has been confirmed by deleting gene CPUR_05437, which led to the abolishment of secalonic acid production [24]. In our effort to find the biosynthetic gene cluster, the gene pc16g10750 of P. chrysogenum wisconsin 54-1255 showed the highest identity with the gene CPUR_05437 (71%) by the NCBI BLAST. Pc16g10750 putatively encodes an iterative nonreducing PKS (NR-PKS) and has a domain architecture of KS-AT-PT-ACP, as ascertained by NCBI Conserved Domains. In these special types of NR-PKSs lacking the thioesterase (TE) domain, polyketide is released from the PKS by a metallo-β-lactamase-type thioesterase (MβL-TE) [24]. The functions of the upstream and downstream genes were also analyzed by BLAST analysis, indicating the integrated gene cluster composed of 23 Open Reading Frames (ORFs) (Supplementary Materials, Figure S24). The gene cluster included one NR-PKS (pc16g10750), one O-methyltransferase (pc16g10740), two decarboxylases (pc16g10730 and pc16g10800), two major facilitator superfamily proteins (pc16g10710 and pc16g10850), two fungal specific transcription factors (pc16g10640 and pc16g10860), ten oxidases or reductases, and five function-unknown genes (Supplementary Materials, Table S4). Finally, the plausible biosynthetic pathway of chrysoxanthones was depicted in Scheme 1. The route followed the sequence octaketide–anthraquinone–benzophenone–tetrahydroxanthone–β-methyl-γ-lactone–chrysoxanthone. As supposed in the Scheme 1, β-methyl-γ-lactone moiety was derived from the tetrahydroxanthone segment, while the absolute configurations of its chiral carbons (marked with the red stars) were not in accordance with that of the obtained tetrahydroxanthones. Hence, more tetrahydroxanthones with other absolute configurations may be discovered in the future.

3. Materials and Methods

3.1. General

Optical rotations were obtained on a JASCO P-2000 digital polarimeter (JASCO, Tokyo, Japan). UV spectra were recorded on a V-650 spectrometer (JASCO, Tokyo, Japan). Circular dichroism (CD) spectra were measured on a JASCO J-815 CD spectrometer (JASCO, Tokyo, Japan). IR spectra were collected on a Nicolet 5700 FT-IR microscope instrument (FT-IR microscope transmission) (Thermo Electron Corporation, Madison, WI, USA). 1H and 13C NMR and 2D NMR spectra were acquired at 500 and 125 MHz on a Bruker AVANCE 500-III instrument (Bruker Biospin Group, Karlsruhe, Germany) in chloroform-d with TMS as an internal reference, and chemical shifts were recorded as δ values. HR-ESI-MS data were measured using an Agilent 1100 LC/MSD Trap SL LC/MS/MS spectrometer (Agilent Technologies Ltd., Santa Clara, CA, USA). HPLC analysis of the secondary metabolites of the crude extracts was performed on an Agilent 1200 HPLC system (Agilent Technologies Ltd., Santa Clara, CA, USA), using a Cosmosil C18 column (5 μM, 4.6 × 150 mm, Nacalai Tesque, Inc., Kyoto, Japan). An HPLC system equipped with a Shimadzu LC-6AD pump, a Shimadzu SPD-20A prominence UV-VIS detector (Shimadzu Corporation, Kyoto, Japan), and an Agilent C18 column (5 μM, 250 × 9.6 mm) was used for semipreparative HPLC. Column chromatography was performed with silica gel (60–100 mesh, 200–300 mesh, Qingdao Marine Chemical Ltd., Qingdao, China), RP-18 (40–60 μM, GE Healthcare, Fairfield, CT, USA), and Sephadex LH-20 (18–110 M, GE healthcare, Fairfield, CT, USA).

3.2. Fungal Material and Fermentation

The fungal strain HLS111 was isolated from a Gelliodes carnosa sponge collected from Lingshui Bay, Hainan Province, China. It was identified as P. chrysogenum on the basis of morphology and internal transcribed spacer (ITS) sequence analysis. The sequence data have been deposited at GenBank as FJ770066 [25]. The fungus HLS111 was first cultivated on YPD agar plates (YPD: yeast extract 10 g, peptone 20 g, glucose 20 g, natural seawater 1 L, pH 7.0–7.2) at 28 °C for 3 days. Then, the mycelia were inoculated into 500 mL Erlenmeyer flasks, each containing 100 mL of liquid YPD medium. The flasks were incubated at 28 °C on a rotary shaker (220 rpm) for 3 days to prepare seed culture. The rice medium was used for solid fermentation, with each 500 mL Erlenmeyer flask containing 100 g rice and 100 mL natural seawater sterilized at 121 °C for 15 minutes. The test-group fermentation was carried out in 25 Erlenmeyer flasks with the HDAC inhibitor VPA at a final concentration of 10 μM, and the control-group fermentation was performed in 3 Erlenmeyer flasks. The flasks were inoculated with 20 mL of seed cultures and incubated at 28 °C for 30 days.

3.3. Extraction, HPLC Analysis, and Isolation

The fermented material was extracted with EtOAc (v/v 1:3) 3 times by ultrasound, and the organic solvent was evaporated to dryness under vacuum to afford the crude extract (the test group was 45 g and the control group was 4 g). The samples (10 mg/mL) of the test and control groups were analyzed with an Agilent 1200 HPLC system using a Cosmosil C18 column (4.6 × 150 mm, 5 μm) with a solvent gradient from 10% to 100% solvent B (solvent A: H2O, solvent B: CH3OH) over the course of 0 to 30 min and 100% solvent B over 30 to 40 min and UV detection at 230 nm at a flow rate of 1 mL/min.
The crude extract of the test group was first fractionated through vacuum liquid chromatography over a silica-gel column (8 × 100 cm, 1100 g), using a gradient elution with petroleum ether-EtOAc-CH3OH, (petroleum ether; petroleum ether-EtOAc = 100:1, 50:1, 20:1, 10:1, 5:1, 2:1, 1:1; EtOAc; CH3OH; v/v, each 2.5 L) to give 10 fractions (Fractions A–J). Fraction E (petroleum ether-EtOAc 10:1, 5.6 g) was further submitted to ODS CC (4 × 60 cm, 200 g) using a stepped gradient elution of CH3OH-H2O (20%, 50%, 80%, and 100%, v/v, each 1.5 L) to afford 4 subfractions E1–E4. Purification of the E4 subfraction (100% CH3OH, 800 mg) by semipreparative HPLC on an Agilent C18 column (9.6 × 250 mm, 5 μm) with 47% CH3CN in H2O as the mobile phase (flow rate 4 mL/min) afforded compounds 13 (compound 1, 3.0 mg, tR = 34.5 min; compound 2, 8.3 mg, tR = 26.7 min; compound 3, 4.1 mg, tR = 44.2 min). The isolation of the known compounds was shown in supporting information.

3.4. Spectroscopic Data

Chrysoxanthone A (1). Pale yellow powder; [ α [ D 20 +30.8 (c 0.05, MeOH); UV (MeOH) λmax (log ε) 248.2 (3.6), 335.5 (3.6); CD (c 7.84 × 10−4 mol/L, MeOH), λmax (Δε) 219 (−7.1), 264 (−2.7), 316.5 (1.6), 366.5 (4.3) nm; IR (KBr) νmax: 3519, 2959, 1792, 1741, 1613, 1566, 1433, 1360, 1213, 1060, 1022, 819 cm−1; 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) see Table 1; HR-ESI-MS (positive): m/z 639.1716 [M + H]+ (Calcd. for C32H31O14, 639.1714).
ChrysoxanthoneB (2). Pale yellow powder; [ α [ D 20 +58.4 (c 0.15, MeOH); UV (MeOH) λmax (log ε) 248.2 (3.6), 335.5 (3.6); CD (c 7.84 × 10−4 mol/L, MeOH), λmax (Δε) 225 (−20.9), 329 (6.4) nm; IR (KBr) νmax: 3511, 2958, 1792, 1741, 1613, 1566, 1434, 1359, 1211, 1060, 1023, 819 cm−1; 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) see Table 1; HR-ESI-MS (positive): m/z 639.1712 [M + H]+ (Calcd. for C32H31O14, 639.1714).
ChrysoxanthoneC (3). Pale yellow powder; [ α [ D 20 +33.2 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 248.2 (3.6), 335.5 (3.6); CD (c 7.84 × 10−4 mol/L, MeOH), λmax (Δε) 242.5 (−6.1), 266 (−6.2), 369 (5.9) nm; IR (KBr) νmax: 3511, 2958, 1792, 1741, 1613, 1566, 1434, 1359, 1211, 1060, 1023, 819 cm−1; 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) see Table 1; HR-ESI-MS (positive): m/z 639.1713 [M + H]+ (Calcd. for C32H31O14, 639.1714).

3.5. ECD Calculation

TD-DFT calculations were executed with Gaussian 09 [26] (Gaussian, Inc., Pittsburgh, PA, USA). Conformational analysis was initially performed using Confab [27] at MMFF94 force field for all relative configurations of each compound. The conformers with lower energies (Boltzmann population of over 1%) were chosen for ECD calculations (Supplementary Materials, Table S1). The conformers were first optimized at PM6 using a semiempirical theory method and further at B3LYP/6-311G** in MeOH using the CPCM polarizable conductor calculation model (Supplementary Materials, Table S2). ECD calculations were conducted in MeOH using TD-DFT, and a total of 50 excited states were calculated. The BP86/6-311G** method was used for compounds 1 and 2, while the TD-DFT theory level for compound 3. The ECD and UV-Vis spectra were simulated in SpecDis [28] by overlapping Gaussian functions for each transition, and summed up by Boltzmann weights.

3.6. Biological Assay

Antibacterial and in vitro antitumor assays were performed for the isolated compounds (>90% purity).

3.6.1. Antibacterial Activity

The antibacterial activities (represented by MIC values) of compounds 13 against 5 bacteria strains, B. subitlis ATCC 63501, S. aureus ATCC 29213, S. epidermidis ATCC 12228, E. faecalis ATCC 29212, and E. coli ATCC 25922, were evaluated by a 96-well plate-based assay [29]. The bacterial strains cultured in LB medium were collected at OD600 of 0.3~0.5, then diluted to OD600 of 5 × 10−4. Aliquots of this suspension (100 μL) were transferred into a 96-well plate. The tested compounds were added into the bacteria suspensions to give the desired concentration, and each concentration had triplicate values. The wells containing the same number of cells but no compounds were set as control groups. Ampicillin was used as the positive control. The 96-well-plates were then incubated at 37 °C for 18 h. The plates were then read using a microplate reader at 600 nm. MIC value was determined by the OD600 with the control without bacteria.

3.6.2. Antitumor Activity

The antitumor activities (in vitro, represented by IC50 values) of compounds 13 against 5 tumor cell lines, human multiform glioblastoma (U87 MG), human nonsmall cell lung cancer (NCI-H1650), human colonic carcinoma (HT29), human renal carcinoma (A498), and human leukemia (HL60), were evaluated with the MTT method, and secalonic acid D was used as the positive control. The detailed methodology for biological testing has already been described in a previous report [30].

4. Conclusions

Three new compounds, chrysoxanthones A–C (13), along with 17 known compounds (420) were isolated from the strain P. chrysogenum HLS111 cultivated with the histone-deacetylase inhibitor VPA. Our present findings revealed that histone-deacetylase inhibitors could activate diversified compound production or increase the yields of fungal secondary metabolites. Considering the instability and high cost of inhibitors, further deletion of genes related to epigenetic modifications still needs to be conducted.

Supplementary Materials

The following are available online at https://www.mdpi.com/1660-3397/16/10/357/s1: Figure S1: Chemical structures of the known compounds 420; Figure S2: (+)-HRESIMS spectrum of chrysoxanthone A (1); Figure S3: IR spectrum of chrysoxanthone A (1); Figure S4: 1H NMR spectrum of chrysoxanthone A (1) in CDCl3; Figure S5: 13C NMR spectrum of chrysoxanthone A (1) in CDCl3; Figure S6: HMBC spectrum of chrysoxanthone A (1) in CDCl3; Figure S7: ROESY spectrum of chrysoxanthone A (1) in CDCl3; Figure S8: (+)-HRESIMS spectrum of chrysoxanthone B (2); Figure S9: IR spectrum of chrysoxanthone B (2); Figure S10: 1H NMR spectrum of chrysoxanthone B (2) in CDCl3; Figure S11: 13C NMR spectrum of chrysoxanthone B (2) in CDCl3; Figure S12: HMBC spectrum of chrysoxanthone B (2) in CDCl3; Figure S13: ROESY spectrum of chrysoxanthone B (2) in CDCl3; Figure S14: (+)-HRESIMS spectrum of chrysoxanthone C (3); Figure S15: IR spectrum of chrysoxanthone C (3); Figure S16: 1H NMR spectrum of chrysoxanthone C (3) in CDCl3; Figure S17: 13C NMR spectrum of chrysoxanthone C (3) in CDCl3; Figure S18: HMBC spectrum of chrysoxanthone C (3) in CDCl3; Figure S19: ROESY spectrum of chrysoxanthone C (3) in CDCl3; Table S1: Energies of dominative conformers of compounds 13 at MMFF94 force field; Table S2: Energies of the conformers of compounds 13 at B3LYP/6-311G** in methanol; Table S3: 1H (500 MHz) and 13C NMR (125 MHz) spectroscopic data (δ in ppm, J in Hz) for compound 4 in CDCl3; Figure S20: 1H NMR spectrum of andrastin A (4, in keto form) in CDCl3; Figure S21: 13 C NMR spectrum of andrastin A (4, in keto form) in CDCl3; Figure S22: HSQC spectrum of andrastin A (4, in keto form) in CDCl3; Figure S23: HMBC spectrum of andrastin A (4, in keto form) in CDCl3; Figure S24: Proposed biosynthetic gene cluster (pc16g10640-pc16g10860) of compounds 13; Table S4: Putative ORFs and predicted functions of gene cluster pc16g10640-pc16g10860; Table S5: Antitumor activities (in vitro IC50, μM) of compounds 13.

Author Contributions

X.Z. and T.G. designed and performed the experiments, and drafted the manuscript; Y.-H.W. and D.-J.Y. helped to analyze the data; J.-J.C. contributed the antibacterial bioassays; P.Z. conceived, designed, and supervised the study, and revised the manuscript. All authors approved the final manuscript.

Funding

This research was funded by the CAMS Innovation Fund for Medical Sciences (CIFMS) grant number (2017-I2M-4-004).

Acknowledgments

We are grateful to the Department of Instrumental Analysis of our Institute for measurement of the NMR and MS. We acknowledge the research Team of Yan Li, Department of Pharmacology of our Institute for the in vitro antitumor bioassays.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Van den Berg, M.A.; Albang, R.; Albermann, K.; Badger, J.H.; Daran, J.M.; Driessen, A.J.; Garcia-Estrada, C.; Fedorova, N.D.; Harris, D.M.; Heijne, W.H.; et al. Genome sequencing and analysis of the filamentous fungus Penicillium chrysogenum. Nat. Biotechnol. 2008, 26, 1161–1168. [Google Scholar] [CrossRef] [PubMed]
  2. Asai, T.; Chung, Y.-M.; Sakurai, H.; Ozeki, T.; Chang, F.-R.; Yamashita, K.; Oshima, Y. Tenuipyrone, a novel skeletal polyketide from the entomopathogenic fungus, Isaria tenuipes, cultivated in the presence of epigenetic modifiers. Org. Lett. 2011, 14, 513–515. [Google Scholar] [CrossRef] [PubMed]
  3. Asai, T.; Morita, S.; Shirata, N.; Taniguchi, T.; Monde, K.; Sakurai, H.; Ozeki, T.; Oshima, Y. Structural diversity of new C13-polyketides produced by Chaetomium mollipilium cultivated in the presence of a NAD+-dependent histone deacetylase Inhibitor. Org. Lett. 2012, 14, 5456–5459. [Google Scholar] [CrossRef] [PubMed]
  4. Bai, J.; Mu, R.; Dou, M.; Yan, D.; Liu, B.; Wei, Q.; Wan, J.; Tang, Y.; Hu, Y. Epigenetic modification in histone deacetylase deletion strain of Calcarisporium arbuscula leads to diverse diterpenoids. Acta Pharm. Sin. B 2018, 8, 687–697. [Google Scholar] [CrossRef] [PubMed]
  5. Mao, X.M.; Xu, W.; Li, D.; Yin, W.B.; Chooi, Y.H.; Li, Y.Q.; Tang, Y.; Hu, Y.-C. Epigenetic genome mining of an endophytic fungus leads to the pleiotropic biosynthesis of natural products. Angew. Chem. Int. Ed. 2015, 54, 7592–7596. [Google Scholar] [CrossRef] [PubMed]
  6. El-Elimat, T.; Figueroa, M.; Raja, H.A.; Graf, T.N.; Swanson, S.M.; Falkinham, J.O., 3rd; Wani, M.C.; Pearce, C.J.; Oberlies, N.H. Biosynthetically distinct cytotoxic polyketides from Setophoma terrestris. Eur. J. Org. Chem. 2015, 2015, 109–121. [Google Scholar] [CrossRef] [PubMed]
  7. Arunpanichlert, J.; Rukachaisirikul, V.; Tadpetch, K.; Phongpaichit, S.; Hutadilok-Towatana, N.; Supaphon, O.; Sakayaroj, J. A dimeric chromanone and a phthalide: Metabolites from the seagrass-derived fungus Bipolaris sp. PSU-ES64. Phytochem. Lett. 2012, 5, 604–608. [Google Scholar] [CrossRef]
  8. Wu, G.; Yu, G.; Kurtan, T.; Mandi, A.; Peng, J.; Mo, X.; Liu, M.; Li, H.; Sun, X.; Li, J.; et al. Versixanthones A–F, cytotoxic xanthone-chromanone dimers from the marine-derived fungus Aspergillus versicolor HDN1009. J. Nat. Prod. 2015, 78, 2691–2698. [Google Scholar] [CrossRef] [PubMed]
  9. Uchida, R.; Shiomi, K.; Inokoshi, J.; Sunazuka, T.; Tanaka, H.; Iwai, Y.; Takayanagi, H.; Omura, S. Andrastins A–C, new protein farnesyltransferase inhibitors produced by Penidllium sp. FO-3929. J. Antibiot. 1996, 49, 418–424. [Google Scholar] [CrossRef] [PubMed]
  10. Omura, S.; Inokoshi, J.; Uchida, R.; Shiomi, K.; Masuma, R.; Kawakubo, T.; Tanaka, H.; Iwai, Y.; Kosemura, S.; Yamamura, S. Andrastins A–C, new protein farnesyltransferase inhibitors produced by Penicillium sp. FO-3929. I. Producing strain, fermentation, isolation, and biological activities. J. Antibiot. 1996, 49, 414–417. [Google Scholar] [CrossRef] [PubMed]
  11. Steyn, P. The isolation, structure and absolute configuration of secalonic acid D, the toxic metabolite of Penicillium oxalicum. Tetrahedron 1970, 26, 51–57. [Google Scholar] [CrossRef]
  12. Andersen, R.; Buechi, G.; Kobbe, B.; Demain, A.L. Secalonic acids D and F are toxic metabolites of Aspergillus aculeatus. J. Org. Chem. 1977, 42, 352–353. [Google Scholar] [CrossRef] [PubMed]
  13. Kurobane, I.; Vining, L.C.; MCINNES, A.G. Biosynthetic relationships among the secalonic acids. J. Antibiot. 1979, 32, 1256–1266. [Google Scholar] [CrossRef] [PubMed]
  14. Elsässer, B.; Krohn, K.; Flörke, U.; Root, N.; Aust, H.J.; Draeger, S.; Schulz, B.; Antus, S.; Kurtán, T. X-ray structure determination, absolute configuration and biological activity of phomoxanthone A. Eur. J. Org. Chem. 2005, 2005, 4563–4570. [Google Scholar] [CrossRef]
  15. Gong, T.; Sun, C.-Y.; Zhen, X.; Qiu, J.-Z.; Yang, J.-L.; Zhu, P. Bioactive metabolites isolated from the fungus Penicillium chrysogenum HLS111 associated with the marine sponge Gelliodes carnosa. Chin. Med. Biotechnol. 2014, 9, 174–179. [Google Scholar]
  16. Mutanyatta, J.; Matapa, B.G.; Shushu, D.D.; Abegaz, B.M. Homoisoflavonoids and xanthones from the tubers of wild and in vitro regenerated Ledebouria graminifolia and cytotoxic activities of some of the homoisoflavonoids. Phytochemistry 2003, 62, 797–804. [Google Scholar] [CrossRef]
  17. Wang, Q.X.; Bao, L.; Yang, X.L.; Guo, H.; Yang, R.N.; Ren, B.; Zhang, L.X.; Dai, H.Q.; Guo, L.D.; Liu, H.W. Polyketides with antimicrobial activity from the solid culture of an endolichenic fungus Ulocladium sp. Fitoterapia 2012, 83, 209–214. [Google Scholar] [CrossRef] [PubMed]
  18. Xu, R.; Li, X.-M.; Wang, B.-G. Penicisimpins A–C, three new dihydroisocoumarins from Penicillium simplicissimum MA-332, a marine fungus derived from the rhizosphere of the mangrove plant Bruguiera sexangula var. rhynchopetala. Phytochem. Lett. 2016, 17, 114–118. [Google Scholar] [CrossRef]
  19. Nozawa, K.; Nakajima, S. Isolation of radicicol from Penicillium luteo-aurantium, and meleagrin, a new metabolite from Penicillium meleagrinum. J. Nat. Prod. 1979, 42, 374–377. [Google Scholar] [CrossRef]
  20. Nagel, D.W.; Pachler, K.G.; Steyn, P.S.; Vleggaar, R.; Wessels, P.L. The chemistry and 13C NMR assignments of oxaline, a novel alkaloid from Penicillium oxalicum. Tetrahedron 1976, 32, 2625–2631. [Google Scholar] [CrossRef]
  21. Ohmomo, S.; Utagawa, T.; Abe, M. Identification of roquefortine C produced by Penicillium roqueforti. Agric. Biol. Chem. 1977, 41, 2097–2098. [Google Scholar] [CrossRef]
  22. Song, F.; He, H.; Ma, R.; Xiao, X.; Wei, Q.; Wang, Q.; Ji, Z.; Dai, H.; Zhang, L.; Capon, R.J. Structure revision of the penicillium alkaloids haenamindole and citreoindole. Tetrahedron Lett. 2016, 57, 3851–3852. [Google Scholar] [CrossRef]
  23. Du, L.; Li, D.; Zhu, T.; Cai, S.; Wang, F.; Xiao, X.; Gu, Q. New alkaloids and diterpenes from a deep ocean sediment derived fungus Penicillium sp. Tetrahedron 2009, 65, 1033–1039. [Google Scholar] [CrossRef]
  24. Neubauer, L.; Dopstadt, J.; Humpf, H.-U.; Tudzynski, P. Identification and characterization of the ergochrome gene cluster in the plant pathogenic fungus Claviceps purpurea. Fungal Biol. Biotechnol. 2016, 3, 2. [Google Scholar] [CrossRef] [PubMed]
  25. Liu, W.C.; Li, C.Q.; Zhu, P.; Yang, J.L.; Cheng, K.D. Phylogenetic diversity of culturable fungi associated with two marine sponges: Haliclona simulans and Gelliodes carnosa, collected from the Hainan Island coastal waters of the South China Sea. Fungal Divers. 2010, 42, 1–15. [Google Scholar] [CrossRef]
  26. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; et al. Gaussian09, R.A. 1, Gaussian Inc.: Wallingford, CT, USA, 2009.
  27. O’Boyle, N.M.; Vandermeersch, T.; Hutchison, G.R. Confab—Generation of diverse low energy conformers. J Cheminform. 2011, 3, P32. [Google Scholar] [CrossRef]
  28. Bruhn, T.; Schaumloeffel, A.; Hemberger, Y.; Bringmann, G. SpecDis: Quantifying the comparison of calculated and experimental electronic circular dichroism spectra. Chirality 2013, 25, 243–249. [Google Scholar] [CrossRef] [PubMed]
  29. Zhang, Q.; Wang, Q.; Xu, S.; Zuo, L.; You, X.; Hu, H.-Y. Aminoglycoside-based novel probes for bacterial diagnostic and therapeutic applications. Chem. Commun. 2017, 53, 1366–1369. [Google Scholar] [CrossRef] [PubMed]
  30. Zhen, X.; Gong, T.; Liu, F.; Zhang, P.-C.; Zhou, W.-Q.; Li, Y.; Zhu, P. A new analogue ofechinomycin and a new cyclic dipeptide from a marine-derived Streptomyces sp. LS298. Mar. Drugs 2015, 13, 6947–6961. [Google Scholar] [CrossRef] [PubMed]
Figure 1. High Performance Liquid Chromatography (HPLC) analysis of the secondary metabolites of P. chrysogenum HLS111. (A) Test group (with valproic acid (VPA)). Peak numbers match the compound numbers in Figure 2 and Supplementary Materials Figure S1. (B) Control group.
Figure 1. High Performance Liquid Chromatography (HPLC) analysis of the secondary metabolites of P. chrysogenum HLS111. (A) Test group (with valproic acid (VPA)). Peak numbers match the compound numbers in Figure 2 and Supplementary Materials Figure S1. (B) Control group.
Marinedrugs 16 00357 g001
Figure 2. Chemical structures of compounds 13.
Figure 2. Chemical structures of compounds 13.
Marinedrugs 16 00357 g002
Figure 3. Key HMBC correlations of compounds 13.
Figure 3. Key HMBC correlations of compounds 13.
Marinedrugs 16 00357 g003
Figure 4. (A) Key Rotating Frame Overhauser Effect Spectroscopy (ROESY) correlations of β-methyl-γ-lactone moiety in compounds 1 and 2; (B) key ROESY correlations of β-methyl-γ-lactone moiety in compound 3; (C) key ROESY correlations of tetrahydroxanthone moiety in compounds 13.
Figure 4. (A) Key Rotating Frame Overhauser Effect Spectroscopy (ROESY) correlations of β-methyl-γ-lactone moiety in compounds 1 and 2; (B) key ROESY correlations of β-methyl-γ-lactone moiety in compound 3; (C) key ROESY correlations of tetrahydroxanthone moiety in compounds 13.
Marinedrugs 16 00357 g004
Figure 5. Experimentally measured and calculated electronic circular dichroism (ECD) spectra for compounds 13.
Figure 5. Experimentally measured and calculated electronic circular dichroism (ECD) spectra for compounds 13.
Marinedrugs 16 00357 g005
Scheme 1. Plausible biosynthetic pathway of chrysoxanthones. Note: chiral carbons were marked with the red stars.
Scheme 1. Plausible biosynthetic pathway of chrysoxanthones. Note: chiral carbons were marked with the red stars.
Marinedrugs 16 00357 sch001
Table 1. 1H (500 MHz) and 13C NMR (125 MHz) data of compounds 13 in CDCl3.
Table 1. 1H (500 MHz) and 13C NMR (125 MHz) data of compounds 13 in CDCl3.
Position1 and 23
δH, mult, J in HzδCδH, mult, J in HzδC
1 159.3 159.3
2 117.7 117.8
37.46, d, 8.5140.17.46, d, 8.5140.2
46.63, d, 8.5107.56.62, d, 8.5107.6
4a 158.4 158.3
53.93, dd, 11.5, 2.576.93.93, dd, 11.0, 1.576.9
62.42, m29.22.42, m29.2
7a2.32, dd, 19.0, 10.536.22.31, dd, 19.0, 10.536.3
7b2.74, dd, 19.0, 6.5 2.74, dd, 19.0, 6.5
8 177.6 177.6
8a 101.5 101.5
9 187.1 187.1
9a 106.8 106.8
10a 84.7 84.7
111.18, d, 6.518.01.17, d, 6.518.0
12 170.2 170.2
133.73, s53.33.73, s53.3
1-OH11.72, s 11.72, s
5-OH2.78, d, 2.5 2.80, br s
8-OH13.76, s 13.78, s
2′ 84.2 84.3
3a’3.05, d, 17.039.63.10, d, 17.040.4
3b’3.21, d, 17.0 3.51, d, 17.0
4′ 194.0 195.0
4a’ 107.6 107.3
5′ 159.2 159.1
6′ 118.1 118.0
7′7.52, d, 8.5141.37.51, d, 8.5141.1
8′6.62, d, 8.5107.36.57, d, 8.5107.0
8a’ 158.6 158.6
9′4.45, d, 4.087.54.38, d, 3.586.4
10′2.84, m30.02.88, m29.6
11a’2.92, dd, 17.5, 9.036.03.03, dd, 18.0,9.036.2
11b’2.23, dd, 17.5, 4.0 2.23, dd, 18.0,4.0
12′ 175.2 175.5
13′1.29, d, 7.020.91.19, d, 7.020.6
14′ 168.8 169.0
15′3.77, s53.73.78, s53.7
5′-OH11.89, s 11.92, s
Table 2. Minimum inhibitory concentrations (MIC, μg/mL) of compounds 13.
Table 2. Minimum inhibitory concentrations (MIC, μg/mL) of compounds 13.
CompoundsMICs (μg/mL)
Staphylococcus epidermidis
ATCC 12228
Staphylococcus aureus
ATCC 29213
Bacillus subtilis
ATCC 63501
Enterococcus faecalis
ATCC 29212
Escherichia coli
ATCC25922
1------5--->100
210205>100>100
3208010>100>100
Ampicillin6.256.253.126.2525
Note: “---” represents untested.

Share and Cite

MDPI and ACS Style

Zhen, X.; Gong, T.; Wen, Y.-H.; Yan, D.-J.; Chen, J.-J.; Zhu, P. Chrysoxanthones A–C, Three New Xanthone–Chromanone Heterdimers from Sponge-Associated Penicillium chrysogenum HLS111 Treated with Histone Deacetylase Inhibitor. Mar. Drugs 2018, 16, 357. https://doi.org/10.3390/md16100357

AMA Style

Zhen X, Gong T, Wen Y-H, Yan D-J, Chen J-J, Zhu P. Chrysoxanthones A–C, Three New Xanthone–Chromanone Heterdimers from Sponge-Associated Penicillium chrysogenum HLS111 Treated with Histone Deacetylase Inhibitor. Marine Drugs. 2018; 16(10):357. https://doi.org/10.3390/md16100357

Chicago/Turabian Style

Zhen, Xin, Ting Gong, Yan-Hua Wen, Dao-Jiang Yan, Jing-Jing Chen, and Ping Zhu. 2018. "Chrysoxanthones A–C, Three New Xanthone–Chromanone Heterdimers from Sponge-Associated Penicillium chrysogenum HLS111 Treated with Histone Deacetylase Inhibitor" Marine Drugs 16, no. 10: 357. https://doi.org/10.3390/md16100357

APA Style

Zhen, X., Gong, T., Wen, Y. -H., Yan, D. -J., Chen, J. -J., & Zhu, P. (2018). Chrysoxanthones A–C, Three New Xanthone–Chromanone Heterdimers from Sponge-Associated Penicillium chrysogenum HLS111 Treated with Histone Deacetylase Inhibitor. Marine Drugs, 16(10), 357. https://doi.org/10.3390/md16100357

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop